Janssen In-licenses CAR-Ts for $245 Million Upfront, its 2nd CAR-T Deal with a China Biotech

Janssen Biotech in-licensed CAR-T candidates from a China biotech, paying $245 million upfront to Cellular Biomedicine Group (CBMG) for global ex-China rights to two clinical stage CD20-targeting CAR-T candidates. One of the candidates has already started trials. In a China Phase I study, patients with non-Hodgkin's lymphoma, most of whom were diagnosed with diffuse large B-cell lymphoma (DLBCL), received a novel bispecific CAR-T therapy targeting both CD19 and CD20. A trial targeting CD20 alone will start later this year. In late 2017, Janssen acquired ex-China rights to a Legend Biotech that targets B38M for multiple myeloma, paying $350 million upfront. One year ago, the drug was approved in the US. More details....

Share this with colleagues: